BIOGEN INC (IDP.DE) Fundamental Analysis & Valuation

FRA:IDP • US09062X1037

161.1 EUR
-4 (-2.42%)
Last: Mar 12, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This IDP.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Taking everything into account, IDP scores 5 out of 10 in our fundamental rating. IDP was compared to 83 industry peers in the Biotechnology industry. IDP is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. IDP has a bad growth rate and is valued cheaply. With these ratings, IDP could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

6

1. IDP.DE Profitability Analysis

1.1 Basic Checks

  • In the past year IDP was profitable.
  • In the past year IDP had a positive cash flow from operations.
  • IDP had positive earnings in each of the past 5 years.
  • Each year in the past 5 years IDP had a positive operating cash flow.
IDP.DE Yearly Net Income VS EBIT VS OCF VS FCFIDP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

1.2 Ratios

  • IDP has a Return On Assets of 4.39%. This is in the better half of the industry: IDP outperforms 75.90% of its industry peers.
  • IDP has a better Return On Equity (7.08%) than 77.11% of its industry peers.
  • IDP's Return On Invested Capital of 8.93% is fine compared to the rest of the industry. IDP outperforms 78.31% of its industry peers.
  • IDP had an Average Return On Invested Capital over the past 3 years of 8.93%. This is below the industry average of 12.16%.
  • The last Return On Invested Capital (8.93%) for IDP is above the 3 year average (8.93%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROIC 8.93%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
IDP.DE Yearly ROA, ROE, ROICIDP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • IDP's Profit Margin of 13.07% is fine compared to the rest of the industry. IDP outperforms 77.11% of its industry peers.
  • In the last couple of years the Profit Margin of IDP has declined.
  • IDP has a better Operating Margin (27.94%) than 81.93% of its industry peers.
  • IDP's Operating Margin has declined in the last couple of years.
  • The Gross Margin of IDP (75.69%) is better than 63.86% of its industry peers.
  • IDP's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
IDP.DE Yearly Profit, Operating, Gross MarginsIDP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. IDP.DE Health Analysis

2.1 Basic Checks

  • IDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • IDP has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, IDP has less shares outstanding
  • The debt/assets ratio for IDP has been reduced compared to a year ago.
IDP.DE Yearly Shares OutstandingIDP.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
IDP.DE Yearly Total Debt VS Total AssetsIDP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • IDP has an Altman-Z score of 3.32. This indicates that IDP is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of IDP (3.32) is better than 65.06% of its industry peers.
  • IDP has a debt to FCF ratio of 3.11. This is a good value and a sign of high solvency as IDP would need 3.11 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.11, IDP belongs to the top of the industry, outperforming 83.13% of the companies in the same industry.
  • IDP has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.34, IDP is in line with its industry, outperforming 57.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Altman-Z 3.32
ROIC/WACC1.05
WACC8.49%
IDP.DE Yearly LT Debt VS Equity VS FCFIDP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.68 indicates that IDP has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.68, IDP is in line with its industry, outperforming 55.42% of the companies in the same industry.
  • A Quick Ratio of 2.03 indicates that IDP has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.03, IDP is in line with its industry, outperforming 48.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.03
IDP.DE Yearly Current Assets VS Current LiabilitesIDP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. IDP.DE Growth Analysis

3.1 Past

  • The earnings per share for IDP have decreased by -7.16% in the last year.
  • IDP shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -14.17% yearly.
  • The Revenue has been growing slightly by 2.22% in the past year.
  • IDP shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.96% yearly.
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%

3.2 Future

  • Based on estimates for the next years, IDP will show a small growth in Earnings Per Share. The EPS will grow by 3.53% on average per year.
  • IDP is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.48% yearly.
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue Next Year-3.98%
Revenue Next 2Y-2.43%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IDP.DE Yearly Revenue VS EstimatesIDP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
IDP.DE Yearly EPS VS EstimatesIDP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. IDP.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 12.17 indicates a correct valuation of IDP.
  • IDP's Price/Earnings ratio is rather cheap when compared to the industry. IDP is cheaper than 91.57% of the companies in the same industry.
  • IDP's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.71.
  • The Price/Forward Earnings ratio is 11.57, which indicates a very decent valuation of IDP.
  • IDP's Price/Forward Earnings ratio is rather cheap when compared to the industry. IDP is cheaper than 97.59% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of IDP to the average of the S&P500 Index (23.82), we can say IDP is valued rather cheaply.
Industry RankSector Rank
PE 12.17
Fwd PE 11.57
IDP.DE Price Earnings VS Forward Price EarningsIDP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, IDP is valued cheaper than 90.36% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, IDP is valued cheaper than 95.18% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.52
EV/EBITDA 8.17
IDP.DE Per share dataIDP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of IDP may justify a higher PE ratio.
PEG (NY)2.36
PEG (5Y)N/A
EPS Next 2Y4.3%
EPS Next 3Y4.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IDP.DE Dividend Analysis

5.1 Amount

  • IDP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IDP.DE Fundamentals: All Metrics, Ratios and Statistics

BIOGEN INC

FRA:IDP (3/12/2026, 7:00:00 PM)

161.1

-4 (-2.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)04-29
Inst Owners97.35%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap23.64B
Revenue(TTM)9.89B
Net Income(TTM)1.29B
Analysts73.02
Price Target177.03 (9.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.18%
Min EPS beat(2)20.87%
Max EPS beat(2)21.48%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)17.28%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)17.2%
EPS beat(12)12
Avg EPS beat(12)12.76%
EPS beat(16)15
Avg EPS beat(16)12.81%
Revenue beat(2)2
Avg Revenue beat(2)3.75%
Min Revenue beat(2)1.26%
Max Revenue beat(2)6.23%
Revenue beat(4)4
Avg Revenue beat(4)6.45%
Min Revenue beat(4)1.26%
Max Revenue beat(4)11.62%
Revenue beat(8)6
Avg Revenue beat(8)2.98%
Revenue beat(12)9
Avg Revenue beat(12)2.26%
Revenue beat(16)11
Avg Revenue beat(16)1.92%
PT rev (1m)6.89%
PT rev (3m)13.87%
EPS NQ rev (1m)-13.19%
EPS NQ rev (3m)-11.95%
EPS NY rev (1m)5.69%
EPS NY rev (3m)4.68%
Revenue NQ rev (1m)-1.38%
Revenue NQ rev (3m)-0.78%
Revenue NY rev (1m)1.15%
Revenue NY rev (3m)1.39%
Valuation
Industry RankSector Rank
PE 12.17
Fwd PE 11.57
P/S 2.76
P/FCF 13.52
P/OCF 12.38
P/B 1.5
P/tB 10.55
EV/EBITDA 8.17
EPS(TTM)13.24
EY8.22%
EPS(NY)13.92
Fwd EY8.64%
FCF(TTM)11.92
FCFY7.4%
OCF(TTM)13.01
OCFY8.08%
SpS58.36
BVpS107.73
TBVpS15.27
PEG (NY)2.36
PEG (5Y)N/A
Graham Number179.15
Profitability
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROCE 10.59%
ROIC 8.93%
ROICexc 10.46%
ROICexgc 35.29%
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
FCFM 20.42%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
ROICexc(3y)9.96%
ROICexc(5y)13.03%
ROICexgc(3y)38.5%
ROICexgc(5y)36.85%
ROCE(3y)10.59%
ROCE(5y)12.95%
ROICexgc growth 3Y4.85%
ROICexgc growth 5Y-4.35%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-14.37%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Debt/EBITDA 1.77
Cap/Depr 23.77%
Cap/Sales 1.87%
Interest Coverage 10.46
Cash Conversion 62.22%
Profit Quality 156.18%
Current Ratio 2.68
Quick Ratio 2.03
Altman-Z 3.32
F-Score4
WACC8.49%
ROIC/WACC1.05
Cap/Depr(3y)46.72%
Cap/Depr(5y)49.51%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.77%
Profit Quality(3y)138.91%
Profit Quality(5y)133.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
Revenue Next Year-3.98%
Revenue Next 2Y-2.43%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%
EBIT growth 1Y8.4%
EBIT growth 3Y-4.68%
EBIT growth 5Y-10.91%
EBIT Next Year16.69%
EBIT Next 3Y5.17%
EBIT Next 5Y1.28%
FCF growth 1Y-19.74%
FCF growth 3Y20.95%
FCF growth 5Y-11.3%
OCF growth 1Y-23.33%
OCF growth 3Y16.78%
OCF growth 5Y-12.22%

BIOGEN INC / IDP.DE FAQ

What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.


What is the valuation status for IDP stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.


What is the profitability of IDP stock?

BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.


What is the financial health of BIOGEN INC (IDP.DE) stock?

The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.


What is the expected EPS growth for BIOGEN INC (IDP.DE) stock?

The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to grow by 5.16% in the next year.